Literature DB >> 15228643

Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus.

Gregory A Ordway1, Katalin Szebeni.   

Abstract

Repeated treatment of rats with antidepressant drugs down-regulates tyrosine hydroxylase (TH) in the locus coeruleus (LC). Using this effect as a model system, this study evaluated the antidepressant potential of the atypical antipsychotic drug, olanzapine. In an initial study, rats were treated i.p. with saline, olanzapine (3 mg/kg), or imipramine (15 mg/kg) once daily for 18 d. Three additional groups of rats received the same treatments that were overlapped with reserpine administration (0.5 mg/kg.d for 21 d). In a second study, groups of rats were treated twice daily with saline, olanzapine (5 mg/kg.d), fluoxetine (15 mg/kg.d), or fluoxetine (15 mg/kg.d) plus olanzapine (5 mg/kg.d) for 1, 6, 12 and 18 d. In the initial study, imipramine produced a 45% reduction in LC TH levels, while olanzapine had no effect. In reserpinized rats, olanzapine exhibited an action that was opposite to that of imipramine, although this effect did not reach statistical significance. In the second study, olanzapine treatment alone or in combination with fluoxetine up-regulated TH in the LC, while fluoxetine alone had no effect. When fluoxetine was co-administered, olanzapine-induced increases in LC TH were more robust and occurred earlier in the time-course of treatment. Based on this preclinical model alone, olanzapine did not exhibit typical antidepressant properties. The unique effect of olanzapine to elevate LC TH may result from olanzapine-induced increases in LC activity. Such an action may contribute to novel behavioural effects of this atypical antipsychotic drug, including enhanced attention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228643     DOI: 10.1017/S1461145704004468

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  8 in total

1.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

2.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.

Authors:  Matthew A Seager; Vanessa N Barth; Lee A Phebus; Kurt Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 3.  Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

4.  Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Authors:  Charles H K West; James C Ritchie; Katherine A Boss-Williams; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-27       Impact factor: 5.176

5.  Quantification of Tyrosine Hydroxylase and ErbB4 in the Locus Coeruleus of Mood Disorder Patients Using a Multispectral Method to Prevent Interference with Immunocytochemical Signals by Neuromelanin.

Authors:  Lei Guo; Jochem Stormmesand; Zheng Fang; Qingbin Zhu; Rawien Balesar; Joop van Heerikhuize; Arja Sluiter; Dick Swaab; Ai-Min Bao
Journal:  Neurosci Bull       Date:  2019-01-31       Impact factor: 5.203

Review 6.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

7.  Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients.

Authors:  Tomasz Gos; Dieter Krell; Hendrik Bielau; Ralf Brisch; Kurt Trübner; Johann Steiner; Hans-Gert Bernstein; Zbigniew Jankowski; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

Review 8.  Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.